olfactory receptor family 7 subfamily E member 15 pseudogeneGenealiases: OR11-392 · OR7E42P · OR7E80P · OST001
Q-omics provides the consensus-scored OR7E15P profile across patient tissues and cancer cell-line models. OR7E15P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, OR7E15P is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, OR7E15P RNA expression shows 10,649 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KICH, and TGCT as cancer lineages where OR7E15P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR7E15P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR7E15P survival associations across molecular data types. OR7E15P RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR7E15P RNA expression–survival associations across cancer types. High OR7E15P expression shows unfavorable associations in UVM, PAAD, KIRC, HNSC, BRCA and READ. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for OR7E15P RNA expression.
This table summarizes OR7E15P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for OR7E15P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR7E15P shows lower tumor expression in PRAD and higher tumor expression in KICH, COAD, THCA, UCEC and LUAD. The KICH box plot shows higher OR7E15P RNA expression in tumor versus normal tissue (log2 FC = +0.168, t-test p < 0.001).
This table shows molecular features associated with OR7E15P in patient tissues and cancer cell lines. In patient samples, OR7E15P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
